RxDoctor Payments Data

Saeed Zafar, MD

Nephrology · Columbus, GANPI 1386671659

Payments from drug & device makers

$1,931in general payments, 2019–2025

Across 110 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$295
  • OPKO Pharmaceuticals, LLC$209
  • Calliditas Therapeutics US Inc.$187
  • Ardelyx, Inc.$152
  • Fresenius USA Marketing, Inc.$132
  • Amgen$130
  • plus $826 from 15 others

What the payments were for

  • Food & beverage$1,67287%
  • Education$26013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,931 in reported general payments places this provider in the 50th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia

Medicare billing

Part B allowed, 2024
$148,206
Medicare patients
284
Services billed
1,016

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide11$28,774
Sevelamer Carbonate56$14,390
FarxigaDapagliflozin Propanediol11$10,641
Nifedipine ErNifedipine29$852
Losartan Potassium77$602
Clonidine Hcl62$577
Potassium Chloride35$563
Furosemide115$472
Hydralazine Hcl54$414
Amlodipine Besylate72$368
Calcitriol26$352
Carvedilol52$327
Pantoprazole Sodium12$240
Doxazosin Mesylate11$228
Spironolactone15$180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$132$28,77411 claims
AstraZenecaFarxiga$295$10,64111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 388 nephrology providers in Georgia.

Other nephrology in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →